Login

What Do They Do?

Sells medicines for cancer, immune diseases, and infections through distributors to health care providers in Greater China.

How Do They Make Money?

The company earns money mainly by selling commercial medicines to distributors in Greater China; payment generally follows delivery within a year. It also earns collaboration revenue from promotional activities.

revenue
SegmentShareRevenue
ZEJULA
Sold outright

41%
FY2022: 68%
VYVGART / VYVGART Hytrulo
Sold outright

21%
FY2022: 0.0%
NUZYRA
Sold outright

13%
FY2022: 2.5%
OPTUNE
Sold outright

11%
FY2022: 22%
QINLOCK
Sold outright
7.8%
FY2022: 7.0%
XACDURO
Sold outright
5.0%
FY2022: 0.0%
AUGTYRO
Sold outright
1.2%
FY2022: 0.0%
Other
Sold outright
0.2%

Who Are Their Customers?

The company sells its commercial products to independent third-party distributors in Greater China, who then sell them to health care providers.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 20% from one customer

Do Revenues Turn Into Profits?

No. It lost $175.5M in FY2025.

Operating income, FY2025
−50% of revenue
▲ +19% (Loss) vs FY2024 (−$282.1M, −71%)
Net income, FY2025
−38% of revenue
▲ +32% (Loss) vs FY2024 (−$257.1M, −64%)
Free cash flow, FY2025
−35% of revenue
▲ +28% (Loss) vs FY2024 (−$220.5M, −55%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −7%
vs $116.1M in Q3 FY2025
Net income
▼ −28% (Loss)
vs −$36M in Q3 FY2025
ZEJULA share of product revenue, net vs 36.8% in Q3 FY2025

Growing. Revenue grew 3.2x in 4 years, from $144.3M in FY2021 to $460.2M in FY2025, about 34% a year.

Broader commercial portfolio The commercial portfolio has broadened beyond ZEJULA, Optune, QINLOCK, and NUZYRA to include VYVGART / VYVGART Hytrulo, XACDURO, and AUGTYRO.

Revenue over time
ZEJULA VYVGART / VYVGART Hytrulo NUZYRA OPTUNE QINLOCK XACDURO AUGTYRO Other VYVGART
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support